SODA - Coca-Cola CEO James Quincey Doesn't See Much Impact From Weight-Loss Drugs Highlights Calorie-Conscious Strategy | Benzinga
There has been a lot of talk lately about the impact of weight-loss drugs on food and beverage brands, but Coca-Cola Co (NYSE: KO) chairman and CEO James Quincey says the iconic beverage company is positioned to weather any adverse effects.
KO Stock Pops: Coca-Cola reported sparkling third-quarter financial results on Tuesday, beating analyst estimates on both the top and bottom line.
Despite concerns weight-loss drugs such as Ozempic and Wegovy may be impacting food and snack sales, Coca-Cola delivered strong sales numbers not just on rising prices, but on higher volumes.
The cherry in the soda was that the company also raised its full-year outlook citing confidence in its portfolio of brands and strength across the ...